Multiple myeloma therapies (bortezomib, lenalidomide) and vascular endothelial growth factor (VEGF) inhibitors like bevacizumab have been associated with thrombosis and hypertension by promoting endothelial cell dysfunction (15–18). Here, VEGFA is linked to AL amyloidosis.